A traditional Chinese medicine composition for treating coronary atherosclerotic disease stable angina pectoris and application thereof

Abstract

The present application relates to a kind of traditional Chinese medicine composition for treating coronary atherosclerotic disease stable angina, the traditional Chinese medicine composition is made of the following weight parts of raw medicinal materials: Radix Bupleuri 10-14 parts, Ramulus Cinnamomi 3-7 parts, Herba Agrimoniae 13-17 parts, Salvia Miltiorrhiza 13-17 parts, Radix Paeoniae Alba 3-7 parts, Rhizoma Pinelliae Praeparatum 4-8 parts, Radix Scophularae 3-7 parts, Radix Ginseng 3-7 parts, Radix Glycyrrhizae 1-5 parts, Zingiber officinale 3-7 parts, Fructus Jujubae 4-8 parts.The present application also provides the application of traditional Chinese medicine composition in the preparation of medicine for treating coronary atherosclerotic disease stable angina.The treatment principle of the present application is: regulating liver and unblocking yang, regulating qi and activating blood.The drugs in the present application are used together, and the effect is enhanced, can regulate Ying and Wei, regulate liver qi, unblock chest yang, and unblock blood vessels, so as to achieve the effect of preventing and treating stable angina pectoris of coronary heart disease.The present application can effectively improve the angina pectoris symptoms of patients with stable angina pectoris of coronary heart disease, improve the quality of life of patients, has certain clinical value, and is worth further research and promotion.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating stable angina pectoris of coronary atherosclerotic disease and application thereof. BACKGROUND

[0002] Coronary atherosclerotic heart disease is mainly caused by coronary artery spasm, stenosis or occlusion, resulting in myocardial ischemia, hypoxia and necrosis. The pathological factors are closely related to coronary atherosclerosis. Stable angina pectoris refers to the temporary and severe ischemia and hypoxia of myocardium caused by sudden increase of myocardial load in patients with fixed and severe coronary stenosis, which is manifested as typical angina pectoris. The angina pectoris of the same patient has similar inducements, similar pain sites and properties, similar pain degrees and durations, and similar attack times. The angina pectoris is relieved in similar time after taking nitroglycerin.

[0003] Chinese patent document CN: 106491958A discloses a traditional Chinese medicine compound preparation for treating angina pectoris of coronary heart disease, which is prepared from the following traditional Chinese medicine raw materials: notoginseng 1-3 parts, rhizoma et radice seu radix 1-3 parts, asarum 1-3 parts, radix astragali 3-10 parts, chuanxiong 1-3 parts, ramulus cinnamomi 1-5 parts, limax 1-2 parts, and rhizoma polygonati 2-6 parts. The preparation method of the traditional Chinese medicine compound preparation is also disclosed. The traditional Chinese medicine compound preparation can effectively reduce arteriosclerosis and regulate inflammatory factors, and can be used for treating angina pectoris of coronary heart disease with convenience and less dosage, and has no toxic and side effects.

[0004] However, there is no report on a traditional Chinese medicine composition for treating stable angina pectoris of coronary atherosclerotic disease, which can effectively improve the angina pectoris symptoms of patients with stable angina pectoris of coronary heart disease, improve the life quality of patients, and has certain clinical value, and is worthy of further research and promotion. SUMMARY

[0005] The present application aims at the deficiencies in the prior art, and provides a traditional Chinese medicine composition for treating stable angina pectoris of coronary atherosclerotic disease and application thereof.

[0006] In the first aspect, the present application provides a traditional Chinese medicine composition for treating stable angina pectoris of coronary atherosclerotic disease, which is prepared from the following raw materials: radix bupleuri 10-14 parts, ramulus cinnamomi 3-7 parts, herba agrimoniae 13-17 parts, radix salviae miltiorrhizae 13-17 parts, radix paeoniae alba 3-7 parts, rhizoma pinelliae praeparatum 4-8 parts, radix scrophulariae 3-7 parts, radix ginseng 3-7 parts, radix glycyrrhizae 1-5 parts, zingiber officinale 3-7 parts, and fructus jujubae 4-8 parts.

[0007] As a preferred example, the traditional Chinese medicine composition is made of the following raw medicinal materials by weight: Radix Bupleuri 11-13 parts, Ramulus Cinnamomi 4-6 parts, Agrimoniae Herba 14-16 parts, Radix Salviae Miltiorrhizae 14-16 parts, Radix Paeoniae Alba 4-6 parts, Rhizoma Pinelliae Praeparatum 5-7 parts, Radix Scrophulariae 4-6 parts, Radix Ginseng 4-6 parts, Radix Glycyrrhizae 2-4 parts, Rhizoma Zingiberis Recens 4-6 parts, Fructus Jujubae 5-7 parts.

[0008] As another preferred example, the traditional Chinese medicine composition is made of the following raw medicinal materials by weight: Radix Bupleuri 12 parts, Ramulus Cinnamomi 5 parts, Agrimoniae Herba 15 parts, Radix Salviae Miltiorrhizae 15 parts, Radix Paeoniae Alba 5 parts, Rhizoma Pinelliae Praeparatum 6 parts, Radix Scrophulariae 5 parts, Radix Ginseng 5 parts, Radix Glycyrrhizae 3 parts, Rhizoma Zingiberis Recens 5 parts, Fructus Jujubae 6 parts.

[0009] As another preferred example, the traditional Chinese medicine composition is a decoction, granules, pills or capsules.

[0010] In a second aspect, the present application provides a use of the traditional Chinese medicine composition in the preparation of a medicament for treating stable angina pectoris of coronary atherosclerotic disease.

[0011] The present application has the advantages that: the treatment principle of the present application is to regulate the liver and unblock the yang, and regulate the qi and activate the blood. In the present application, Radix Bupleuri can dredge the liver and gallbladder, Radix Scrophulariae can clear the heat, Ramulus Cinnamomi is pungent and warm, and can invigorate the heart yang and help the heart to move the blood, Ramulus Cinnamomi combined with Radix Paeoniae Alba can unblock the yang and transform the qi to resolve the turbid, Agrimoniae Herba can tonify the heart and strengthen the heart, Radix Salviae Miltiorrhizae can activate the blood and resolve the stasis, and clear the heart and relieve the distress, Radix Ginseng and Radix Glycyrrhizae can help the spleen and stomach to eliminate the evil, Rhizoma Pinelliae can dry dampness, resolve phlegm, descend adverse and harmonize the stomach, Rhizoma Zingiberis Recens and Fructus Jujubae can regulate the spleen and stomach and help the ginseng to benefit the qi and move the fluid. The combination of the above-mentioned medicines can regulate the nutrient and defensive qi, regulate the liver qi, unblock the chest yang, and smooth the blood vessels, thereby achieving the effect of preventing and treating stable angina pectoris of coronary heart disease. The present application can effectively improve the angina pectoris symptoms of patients with stable angina pectoris of coronary heart disease, improve the quality of life of the patients, has certain clinical value, and is worthy of further research and promotion. DETAILED DESCRIPTION

[0012] The present application will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate but not to limit the scope of the present application. Furthermore, it should be understood that those skilled in the art can make various modifications or amendments to the present application after reading the content described in the present application, and these equivalent forms also fall within the scope defined by the claims of the present application.

[0013] Example 1: The traditional Chinese medicine composition for treating stable angina pectoris of coronary atherosclerotic disease (one)

[0014] Radix Bupleuri 12 parts, Ramulus Cinnamomi 5 parts, Agrimoniae Herba 15 parts, Radix Salviae Miltiorrhizae 15 parts, Radix Paeoniae Alba 5 parts, Rhizoma Pinelliae Praeparatum 6 parts, Radix Scrophulariae 5 parts, Radix Ginseng 5 parts, Radix Glycyrrhizae 3 parts, Rhizoma Zingiberis Recens 5 parts, Fructus Jujubae 6 parts.

[0015] Example 2 The Chinese medicine composition of the present application for treating stable angina pectoris of coronary atherosclerotic disease (two)

[0016] Bupleurum 12 parts, Ramulus Cinnamomi 3 parts, Agrimonia 15 parts, Salvia 13 parts, Radix Paeoniae Alba 3 parts, Rhizoma Pinelliae Praeparatum 6 parts, Radix Scrophulariae 3 parts, Radix Ginseng 3 parts, Radix Glycyrrhizae 3 parts, Zingiber officinale 3 parts, Fructus Jujubae 4 parts.

[0017] Example 3 The Chinese medicine composition of the present application for treating stable angina pectoris of coronary atherosclerotic disease (three)

[0018] Bupleurum 14 parts, Ramulus Cinnamomi 5 parts, Agrimonia 17 parts, Salvia 15 parts, Radix Paeoniae Alba 7 parts, Rhizoma Pinelliae Praeparatum 8 parts, Radix Scrophulariae 5 parts, Radix Ginseng 7 parts, Radix Glycyrrhizae 5 parts, Zingiber officinale 5 parts, Fructus Jujubae 8 parts.

[0019] Example 4 The Chinese medicine composition of the present application for treating stable angina pectoris of coronary atherosclerotic disease (four)

[0020] Bupleurum 12 parts, Ramulus Cinnamomi 4 parts, Agrimonia 14 parts, Salvia 15 parts, Radix Paeoniae Alba 4 parts, Rhizoma Pinelliae Praeparatum 5 parts, Radix Scrophulariae 4 parts, Radix Ginseng 5 parts, Radix Glycyrrhizae 2 parts, Zingiber officinale 4 parts, Fructus Jujubae 6 parts.

[0021] Example 5 The Chinese medicine composition of the present application for treating stable angina pectoris of coronary atherosclerotic disease (five)

[0022] Bupleurum 13 parts, Ramulus Cinnamomi 3 parts, Agrimonia 16 parts, Salvia 16 parts, Radix Paeoniae Alba 3 parts, Rhizoma Pinelliae Praeparatum 7 parts, Radix Scrophulariae 5 parts, Radix Ginseng 6 parts, Radix Glycyrrhizae 5 parts, Zingiber officinale 6 parts, Fructus Jujubae 7 parts.

[0023] Example 6 The Chinese medicine composition of the present application for treating stable angina pectoris of coronary atherosclerotic disease (six)

[0024] Bupleurum 10 parts, Ramulus Cinnamomi 5 parts, Agrimonia 13 parts, Salvia 13 parts, Radix Paeoniae Alba 5 parts, Rhizoma Pinelliae Praeparatum 4 parts, Radix Scrophulariae 3 parts, Radix Ginseng 5 parts, Radix Glycyrrhizae 1 part, Zingiber officinale 3 parts, Fructus Jujubae 4 parts.

[0025] Example 7 The Chinese medicine composition of the present application for treating stable angina pectoris of coronary atherosclerotic disease (seven)

[0026] Bupleurum 10 parts, Ramulus Cinnamomi 7 parts, Agrimonia 17 parts, Salvia 17 parts, Radix Paeoniae Alba 7 parts, Rhizoma Pinelliae Praeparatum 8 parts, Radix Scrophulariae 7 parts, Radix Ginseng 6 parts, Radix Glycyrrhizae 2 parts, Zingiber officinale 7 parts, Fructus Jujubae 8 parts.

[0027] Example 8 The Chinese medicine composition of the present application for treating stable angina pectoris of coronary atherosclerotic disease (eight)

[0028] Bupleurum 12 parts, Ramulus Cinnamomi 4 parts, Agrimonia 15 parts, Salvia 14 parts, Radix Paeoniae Alba 4 parts, Rhizoma Pinelliae Praeparatum 5 parts, Radix Scrophulariae 4 parts, Radix Ginseng 4 parts, Radix Glycyrrhizae 2 parts, Rhizoma Zingiberis Recens 4 parts, Fructus Jujubae 5 parts.

[0029] Example 9 Traditional Chinese medicine composition for treating stable angina pectoris of coronary atherosclerotic disease according to the present application (IX)

[0030] Bupleurum 13 parts, Ramulus Cinnamomi 5 parts, Agrimonia 17 parts, Salvia 16 parts, Radix Paeoniae Alba 6 parts, Rhizoma Pinelliae Praeparatum 8 parts, Radix Scrophulariae 6 parts, Radix Ginseng 6 parts, Radix Glycyrrhizae 4 parts, Rhizoma Zingiberis Recens 6 parts, Fructus Jujubae 8 parts.

[0031] Example 10 Preparation of traditional Chinese medicine composition for treating stable angina pectoris of coronary atherosclerotic disease according to the present application (X)

[0032] According to the proportion by weight, the appropriate amount of the pharmaceutical composition is mixed and crushed, and each component of the medicine is mixed with water for heating and leaching. The heating and leaching includes decocting with strong fire and then decocting with weak fire. The decoction is twice, the decoction is combined, the dregs are filtered out, and the leaching liquid is obtained, which is the decoction.

[0033] Example 11 Clinical efficacy experiment

[0034] (1) Case collection: According to the diagnostic criteria of stable angina pectoris, angina pectoris classification criteria and TCM diagnostic criteria, patients with stable angina pectoris and Qi stagnation in the chest were included. The specific diagnostic criteria and scheme are as follows: 1) Diagnostic criteria of stable angina pectoris of coronary heart disease: According to the “Nomenclature and Diagnostic Criteria for Ischemic Heart Disease” issued by the International Society of Cardiology and the World Health Organization Joint Topic Group in 1979 and the “European Society of Cardiology Stable Coronary Artery Disease Management Guidelines” issued in 2013.

[0035] ① Within the past 60 days, the frequency, duration, triggers or relief methods of angina pectoris have not changed, and there is no evidence of recent myocardial injury (normal serum myocardial markers troponin or troponin 1, no abnormal resting electrocardiogram showing ST segment significantly elevated in the shape of arching upward).

[0036] ② Coronary angiography or CTA examination: the stenosis of the main coronary arteries (including left anterior descending branch, right coronary artery, left circumflex branch and left main stem) is between 50%-75%, or the stenosis of the collateral coronary arteries (except the main coronary arteries, such as diagonal branch, etc.) is between 50%-100%.

[0037] 2) Angina pectoris classification criteria:

[0038] Angina classification, reference Canadian Cardiovascular Society Angina Classification Criteria: ① Grade I, general activities such as climbing stairs are not limited, and sustained effort or strong / fast activities can induce angina. ② Grade II, only slightly limited in general physical activity; angina induced by cold, fast walking, mental stress, after meals; limited to climbing more than one floor or walking 200m or more at normal pace. ③ Grade III, limited to climbing one floor or walking <200m on flat ground. ④ Grade IV: angina can occur during light activity or at rest.

[0039] 3) Chest pain - qi stagnation in the chest syndrome diagnostic criteria: reference to the 2017 Zhang Boli, Wu Mianhua edited "Internal Medicine" textbook. With one main symptom and two secondary symptoms, reference to the patient's tongue and pulse can be diagnosed as chest pain - qi stagnation in the chest syndrome. Main symptoms: chest pain, chest tightness, chest distension; secondary symptoms: sighing, palpitations, insomnia, abdominal distension. Dark red tongue, thin or thin greasy fur, thin pulse.

[0040] 4) Inclusion criteria

[0041] ① Meet the diagnostic criteria for stable angina pectoris;

[0042] ② Meet the diagnostic criteria for chest pain - qi stagnation in the chest syndrome;

[0043] ③ The subject is between 40 and 80 years old, including 40 and 80 years old, regardless of gender;

[0044] ④ The subject agrees to participate in the study with informed consent, signs the informed consent form and can cooperate with the treatment.

[0045] 5) Exclusion criteria

[0046] ① Diagnosed as acute myocardial infarction (including necrotic Q wave and non-necrotic Q wave type), unstable angina pectoris, and chest pain caused by conditions such as hyperthyroidism, menopausal syndrome, cholecardia, neurosis, stomach and esophageal reflux, neuritis, trauma, etc.;

[0047] ② With the following factors: such as severe heart failure, cardiogenic shock, severe ventricular arrhythmia, obstructive or dilated cardiomyopathy, pericardial tamponade, severe heart valve disease with unstable hemodynamics, pulmonary embolism, uncontrolled hypertension, and severe infection, etc.;

[0048] ③ Patients who meet the diagnostic criteria for stable angina pectoris but do not follow the guidelines for routine treatment;

[0049] ④ Patients with severe diseases of the liver, kidney, hematopoietic system, and endocrine system;

[0050] ⑤ Patients with mental abnormalities and unwilling to cooperate;

[0051] ⑥ Pregnant, lactating women or women with fertility requirements;

[0052] ⑦Allergic constitution or allergic to multiple drugs;

[0053] ⑧The investigator believes that there are other conditions that are not suitable for participating in this trial.

[0054] (2) Clinical grouping and administration method:

[0055] This study is divided into 2 groups, as follows:

[0056] ① Control group: routine western medicine treatment combined with placebo granules for 4 weeks.

[0057] ② Treatment group: on the basis of routine prescription drug treatment, combined with Tiaogan Tongyang Decoction (Chaihu 12g, Guizhi 5g, Xianhecao 15g, Danshen 15g, Baishao 5g, Zhishanxia 6g, Huangqi 5g, Renshen 5g, Zhigancao 3g, Shengjiang 5g, Dazao 6g), for 4 weeks, the administration method is 100ml warm water after breakfast every day.

[0058] (3) Statistical analysis

[0059] Data were analyzed using SPSS version 26.0 software (IBM Corporation, Armonk, USA). Normality test and variance homogeneity test were used to measure continuous variables. Variables were described as mean and standard deviation. Covariance analysis was used for inter-group comparison, with baseline value as a covariate. Paired t-test was used for intra-group comparison. If the measurement data do not conform to the normal distribution, the statistical description uses median and interquartile range M(Q25, Q75) to represent, and the statistical analysis uses non-parametric rank sum test. Categorical variables were tested using the chi-square test or Fisher's exact test, and variables were described as frequencies (expressed as percentages). Statistical significance was set at a P value of less than 0.05.

[0060] (4) Experimental results

[0061] ① Participant characteristics

[0062] This study recruited 90 eligible participants from December 2020 to July 2022. Finally, 80 subjects (treatment group = 41, control group = 39) completed the clinical trial. The reasons for the participants being excluded from the trial were as follows: unwilling to continue the trial due to personal reasons (n = 4) and acute outbreak of COPD (n = 6). The characteristics of all participants are shown in Table 1, including age, gender, smoking, disease duration, angina classification, and comorbidities. There was no statistically significant difference between the two groups in terms of subject characteristics (P>0.05).

[0063] ② Primary efficacy outcome - angina efficacy

[0064] As shown in Table 1, the total effective rate of angina pectoris in the treatment group was as high as 82.9%, which was significantly better than 61.5% in the control group (P<0.05; Table 2). In the control group, 15 cases (38.5%) were ineffective, 18 cases (46.2%) were effective, and 6 cases (15.4%) were significantly effective; while in the CHGZ group, 7 cases (17.1%) were ineffective, 20 cases (48.8%) were effective, and 14 cases (34.1%) were significantly effective.

[0065] Table 1 Comparison of angina pectoris efficacy between the two groups

[0066]

[0067] ③Secondary efficacy outcome--comparison of nitroglycerin reduction rate

[0068] As shown in Table 2, the total reduction rate of nitroglycerin in the CHGZ group was as high as 78.0%, which was significantly better than 52.8% in the control group (P<0.05; Table 3). In the control group, 17 cases (43.6%) had no change, 16 (41.0%) cases had a reduction, and 6 cases (15.4%) stopped taking nitroglycerin; while in the CHGZ group, 9 cases (22.0%) had no change, 20 (48.8%) cases had a reduction, and 12 cases (29.3%) stopped taking nitroglycerin.

[0069] Table 2 Comparison of nitroglycerin reduction rate between the two groups

[0070]

[0071] ④Comparison of total TCM syndrome score

[0072] The comparison between groups showed that there was a statistically significant difference in the total TCM syndrome score between the CHGZ group and the control group (P<0.05; Table 4). The comparison within groups found that there was a statistically significant difference in the total TCM syndrome score in both the CHGZ group and the control group (P<0.001; Table 3).

[0073] Table 3 Comparison of total TCM syndrome score between / within groups [M(Q25, Q75), (points)]

[0074]

[0075] Note: Compared with before treatment, ** P<0.01; compared between the treatment group and the control group, # P<0.05.

[0076] ⑤Safety evaluation

[0077] The safety indicators of subjects in both groups before and after treatment were within the clinical normal range, and no adverse events occurred.

[0078] (5) Research conclusion

[0079] Tiaogan Tongyang Decoction can effectively improve the symptoms of stable angina pectoris in patients with coronary heart disease, improve the quality of life of patients, and has certain clinical value, and is worthy of further research and promotion.

[0080] Example 12 animal experiment

[0081] Experimental method

[0082] (1) Grouping, modeling and administration

[0083] 50 healthy male SD rats were fed freely, and after adaptive feeding for 1 week, 50 healthy male SD rats were randomly divided into normal group (10 rats), modeling group (40 rats), and modeling group. 40 rats were modeled.

[0084] Modeling method: high-fat diet feeding and intraperitoneal injection of pituitrin to form a rat model of coronary heart disease myocardial ischemia. A total of 36 modeling was successful. 36 rats with stable angina pectoris of coronary heart disease were divided into traditional Chinese medicine group one (9 rats); Traditional Chinese medicine control group one (9 rats); Traditional Chinese medicine control group two: (9 rats); Model group (9 rats).

[0085] Administration method:

[0086] Traditional Chinese medicine group one: (Bupleurum 12 parts, Cinnamomum 5 parts, Herba Agrimoniae 15 parts, Salvia miltiorrhiza 15 parts, Paeonia lactiflora 5 parts, Rhizoma Pinelliae praeparatum 6 parts, Scutellaria 5 parts, Ginseng 5 parts, Radix Glycyrrhizae 3 parts, Zingiber officinale 5 parts, Fructus Jujubae 6 parts) 2 times a day, gavage, treatment for 4 weeks.

[0087] Traditional Chinese medicine control group one: (Bupleurum 12 parts, Cinnamomum 5 parts, Herba Agrimoniae 15 parts, Salvia miltiorrhiza 15 parts, Paeonia lactiflora 5 parts, Rhizoma Pinelliae praeparatum 6 parts, Scutellaria 5 parts, Ginseng 5 parts, Radix Glycyrrhizae 3 parts, Zingiber officinale 5 parts, Fructus Jujubae 6 parts) 2 times a day, gavage, treatment for 4 weeks.

[0088] Traditional Chinese medicine control group two: (Bupleurum 12 parts, Cinnamomum 5 parts, Herba Agrimoniae 15 parts, Salvia miltiorrhiza 15 parts, Paeonia lactiflora 5 parts, Rhizoma Pinelliae praeparatum 6 parts, Scutellaria 5 parts, Ginseng 2 parts, Radix Glycyrrhizae 3 parts, Zingiber officinale 5 parts, Fructus Jujubae 10 parts) 2 times a day, gavage, treatment for 4 weeks.

[0089] The model group was injected with an equal volume of normal saline.

[0090] The normal group was injected with an equal volume of normal saline.

[0091] (2) Observation index

[0092] The serum TG and TC contents of each group of rats with coronary heart disease myocardial ischemia.

[0093] (3) Statistical method

[0094] Statistical analysis was performed using SPSS version 26.0 software (IBM Corporation, Armonk, USA). For measurement data, statistical description was performed using mean ± standard deviation Independent sample t test was used for comparison between groups, and P<0.05 was considered statistically significant.

[0095] (4) Experimental results

[0096] Comparison of serum TG and TC contents of coronary heart disease myocardial ischemia rats in each group

[0097] Note: compared with the normal group, *P<0.05; compared with the model group, # P<0.05.

[0098] Compared with the model group, the serum TG improvement: the first group of the present application is better than the traditional Chinese medicine control group one, better than the traditional Chinese medicine control group two, and better than the model group; compared with the model group, the serum TC improvement: the first group of the present application is better than the traditional Chinese medicine control group two, better than the traditional Chinese medicine control group one, and better than the model group; therefore, after intervention, compared with the model group, the serum TG and TC are decreased; in summary, the curative effect of the present application group is the best.

[0099] The above is only the preferred embodiment of the present application, it should be noted that for ordinary skilled in the art, without departing from the method of the present application, can also make a number of improvements and supplements, these improvements and supplements should also be considered as the protection scope of the present application.

Claims

1. The application of a traditional Chinese medicine composition for treating stable angina pectoris caused by coronary atherosclerosis in the preparation of a medicine for treating qi stagnation in the chest and heart syndrome of stable angina pectoris caused by coronary atherosclerosis, characterized in that, The traditional Chinese medicine composition is made from the following raw materials in parts by weight: Bupleurum chinense 12 parts, Cinnamomum cassia 5 parts, Agrimonia pilosa 15 parts, Salvia miltiorrhiza 15 parts, Paeonia lactiflora 5 parts, processed Pinellia ternata 6 parts, Scutellaria baicalensis 5 parts, Panax ginseng 5 parts, processed Glycyrrhiza uralensis 3 parts, fresh ginger 5 parts, and jujube 6 parts.

2. The application according to claim 1, characterized in that, The traditional Chinese medicine composition is in the form of decoction, granules, pills, or capsules.

Images